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he literature indicates that patients in a cyanotic state 
with congenital heart disease (CHD) might be pro-
tected against atherosclerosis.1,2 Cyanosis is the 
result of a right-to-left shunt. In around 1% of CHD patients, 
cyanosis results from the development of Eisenmenger syn-
drome.3 This syndrome is characterized by severe irrevers-
ible pulmonary vascular disease and reversal of the previous 
right-to-left shunt.4–7
Cyanosis in CHD patients is associated with hemostatic 
abnormalities involving platelets and coagulation mechanisms 
resulting in an increased risk for bleeding and thrombosis.8,9 
In a study by Perloff, signs of atherosclerosis at coronary angi-
ography and in necropsy specimens were missing in cyanotic 
patients.1 Moreover, cyanosis was associated with increased 
anti-thrombotic and anti-atherosclerotic effects such as throm-
bocytopenia and hyperbilirubinemia.10 In addition, high-alti-
tude hypoxemia was related with a reduced total cholesterol 
and low-density lipoprotein (LDL)-cholesterol in combination 
with elevated high-density lipoprotein (HDL)-cholesterol.1,2
Atherosclerosis is a dynamic process characterized by ves-
sel wall remodeling, ultimately leading to an acute cardiovas-
cular event.11 Non-invasive B-mode ultrasound imaging of 
carotid intima – media thickness (IMT) allows for the assess-
ment of early atherosclerotic changes. Carotid IMT is an 
accepted valid marker for the present status of atheroscle-
rosis and future atherosclerotic disease risk.11–13 Carotid IMT 
of cyanotic CHD patients has not yet been studied. In the 
present study we hypothesized that IMT, and hence the ath-
erosclerotic burden, is decreased in cyanotic patients com-
pared to controls. We hypothesized that a decreased IMT 
is accompanied by reduced atherosclerotic risk factors. We 
therefore compared IMT and risk factors for atherosclerosis 
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Background:  Cyanotic patients with congenital heart disease (CHD) might be protected against atherosclerosis.
Methods and Results:  Atherosclerotic risk factors and carotid intima – media thickness (IMT) were investigated 
in adults with cyanotic CHD and in unaffected age- and sex-matched controls. Fifty-four cyanotic patients (30 men, 
mean age 38, range 19–60 years) and 54 controls were included. Mean transcutaneous saturation of the cyanotic 
patients was 81±6%. Mean carotid IMT adjusted for age was significantly decreased in cyanotic patients compared 
to controls (0.55±0.1 mm vs 0.58±0.08 mm: ∆IMT =0.04 mm [SE 0.015], P=0.01).  In cyanotic patients  lower  total 
cholesterol  levels were observed  (4.4±1 mmol/L vs 4.9±1 mmol/L; P=0.02), as well as  lower  thrombocyte  levels 
(173±81×109 /L vs 255±54×109 /L; P<0.01), higher bilirubin levels (18.6±11 μmol/L vs 12.7±6 μmol/L; P<0.01), and 
lower diastolic and systolic blood pressure (71±9 mmHg vs 76±9 mmHg, P<0.01; 113±14 mmHg vs 124±12 mmHg, 
P<0.01, respectively).
Conclusions:  In  patients  with  cyanotic  CHD  carotid  IMT,  and  hence  atherosclerosis  disease  risk,  was  de-
creased. This might be due to a combination of reduced atherosclerotic risk factors such as lower blood pressure, 
lower total cholesterol levels, higher bilirubin levels and lower thrombocyte levels.    (Circ J  2010; 74: 1436 – 1441)
Key Words:  Atherosclerosis; Carotid intima – media thickness; Cyanotic congenital heart disease; Eisenmenger 
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between adult patients with cyanotic CHD and unaffected 
age- and sex-matched controls.
Methods
Patients
For the present study, patients were included from the follow-
ing 6 Dutch hospitals: Academic Medical Center Amsterdam, 
University Medical Center Groningen, Radboud University 
Nijmegen Medical Center, Leiden University Medical Center, 
University Medical Center Utrecht, and St Antonius Hospital 
Nieuwegein, and one Italian hospital: University of Padua. 
Patients with a transcutaneous oxygen saturation <90% at rest 
were defined as cyanotic. Cyanotic CHD patients from the 
Netherlands were identified using the CONCOR database, a 
national registry and DNA bank of adult patients with CHD 
in the Netherlands.14 Italian cyanotic patients were identified 
at the outpatient clinic. Patients were requested to partici-
pate by their cardiologist. Patients with one of the following 
defects were asked to participate: Eisenmenger syndrome, 
univentricular heart, pulmonary atresia with ventricular septal 
defect (VSD), pulmonary atresia without VSD, or double 
outlet right ventricle. Age- and sex-matched controls were 
recruited among relatives and acquaintances by the partici-
pating patients. Patients who had previously undergone a 
Fontan procedure and patients with a liver or kidney disease, 
myeloproliferative disease, current or recent malignancy and 
patients using lipid-lowering drugs were excluded from the 
study.
Study Protocol
This was an observational, case – control study. Data were 
collected during a single visit to the outpatient clinic between 
March 2007 and May 2008. Data on coronary risk factors such 
as body mass index, diastolic and systolic blood pressure, cur-
rent smoking status, positive family history such as parent 
or sibling with a cardiovascular event aged <55 years, medi-
cal history and use of medication such as thiazide diuretics, 
 β-blockers, and lipid lowering drugs were collected both in 
cyanotic patients and in controls. Hypertension was defined 
as diastolic blood pressure >90 mmHg, systolic blood pres-
sure >140 mmHg, or the use of anti-hypertensive agents. 
Furthermore, a fasting venous blood sample was collected. 
Hematologic measurements included hemoglobin concentra-
tion, hematocrit, thrombocyte, and erythrocyte count. Hema-
tocrit was based on automated electronic particle counts. 
Serum tests included glucose, uric acid, total bilirubin, folate 
acid and measurement of lipids. Transcutaneous saturation 
was measured in both patients and controls after 5 min of rest 
using a standard transcutaneous pulse oximeter at the finger.
Atherosclerotic changes were assessed in both cyanotic 
patients and controls by measuring carotid IMT using B-mode 
ultrasound. IMT images of the arterial far wall segments of the 
right and left common carotid artery, carotid bulb and, internal 
carotid artery were acquired according to a standardized pro-
tocol.11 Carotid ultrasound scans of the patients from the 
Academic Medical Center Amsterdam, Leiden University 
Medical Center, University Medical Center Utrecht, Radboud 
University Nijmegen Medical Center and the St Antonius 
Hospital Nieuwegein, The Netherlands, were performed in 
the Academic Medical Center Amsterdam by a single well-
trained and experienced sonographer. IMT measurements of 
subjects of the University Medical Center Groningen (n=13) 
and the University of Padua (n=6) were performed in the re- 
spective centers. In all centers, including the Italian site, scan 
protocols were standardized. The centers in the Netherlands 
used Acuson Aspen or Sequoia equipment, using L7 trans-
ducers and the magnification settings on both machine types 
(Siemens, Erlangen, Germany). In the Padua center images 
were measured online using an Acuson Sequoia, C512, echo-
cardiography system, 4V1C transthoracic Sector Array Trans-
ducer and 6L3 IMT Sector Array Transducer (Siemens). 
Dynamic and high resolution still images were saved as 
DICOM files. Measurements were done on the 2×2-cm still 
frames; the clips were used as a dynamic reference to iden-
tify the lumen – intima and media–adventitia interfaces of 
the arterial far walls. All images were analyzed by the same 
image analyst blinded to clinical information. IMT was 
defined as the average of the IMTs of the right and left com-
mon carotid artery, carotid bulb and internal carotid artery 
segments. The institutional review committee approved the 
protocol and written informed consent was obtained from all 
participants prior to participation in the study. For patients 
with Down syndrome, parental consent was obtained.
Table 1. Subject Characteristics
Cyanotic CHD patients 
(n=54)
Controls 
(n=54) P value
Age (years), mean (range)       38 (19–60)       37 (18–60) 0.3
Gender, male, n (%) 30 (56) 29 (54) 0.5
Mean oxygen saturation (%), mean ± SD 81±6　 100±0.7　 <0.01　
Blood pressure (mmHg), mean ± SD
    Diastolic 71±9　 76±9　 <0.01　
    Systolic 113±14　 124±12　 <0.01　
Use of β-blockers, n (%)   7 (13)   2 (4)　 0.08
Risk factors for atherosclerosis, n (%)
    Thrombotic events   6 (11)   2 (4)　 0.1　
    Hypertension   3 (6)　   9 (17) 0.06
    Mean BMI (kg/m2), mean ± SD 23±4　 24±4　 0.5　
    Hypothyroidism, n (%) 13 (24) 0 <0.01　
    Positive family history CVD, n (%)   5 (9)　   5 (9)　 0.6　
    Smoking, n (%)   3 (6)　   8 (15) 0.1　
CHD, congenital heart disease; BMI, body mass index; CVD, cardiovascular disease.
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Statistical Analysis
The descriptive data are presented as mean ± SD if normally 
distributed or as median (range) as appropriate. Comparisons 
of continuous variables between groups were made using 
unpaired Student t-tests. In the case of a skewed distribution, 
the Mann – Whitney U-test was used. Correlation coefficients 
were used to assess the relationship between IMT and age and 
total cholesterol. Multivariate analysis of mean IMT, total 
cholesterol levels and HDL-cholesterol levels was used to 
assess contributing parameters. P<0.05 was considered to be 
significant.
Results
Patients
Between March 2007 and May 2008, 54 cyanotic patients (30 
men and 24 women, mean age 38 years, range 19–60 years) 
and 54 age- and sex-matched controls were included in the 
study. Mean transcutaneous saturation of the cyanotic pa- 
tients was 81±6%. Eisenmenger syndrome was present in 
89% of the cyanotic patients (n=48), with VSD being the 
most frequent underlying diagnosis. Of the cyanotic patients 
35% (n=19) had Down syndrome, of whom 68% (n=13) 
had hypothyroidism. All patients with hypothyroidism were 
adequately treated. Cyanotic patients had significantly lower 
diastolic and systolic blood pressure compared to controls 
(71±9 mmHg vs 76±9 mmHg, P=0.02; 113±14 mmHg vs 124± 
12 mmHg, P<0.01, respectively). Table 1 lists the population 
characteristics. One cyanotic patient had a previous cere-
brovascular accident and 6 cyanotic patients had a previous 
thrombotic event.
IMT
The results of the B-mode ultrasound IMT measurements 
showed IMT increase with advancing age (r=0.4, P<0.01). 
Moreover, mean carotid IMT, adjusted for age using linear 
regression analysis, was significantly decreased in cyanotic 
patients compared to controls (0.55±0.1 mm vs 0.58±0.08 mm), 
with a mean difference of 0.04 mm (SE 0.015 mm, P=0.01), 
as shown in Figure 1. Sub-segmental analysis, after adjust-
ment for age, showed these differences to be most explicit in 
the common carotid artery (P=0.02) and carotid bulb (P= 
0.004). There was no age×gender interaction in IMT (P=0.9). 
On multivariate linear regression analysis the influence of the 
following parameters was not statistically significant: Down 
syndrome (β=0.070, P=0.6); hypothyroidism (β=0.215, P= 
0.1); current smoking (β=–0.049, P=0.6); use of thiazide 
diuretics (β=–0.005, P=1); use of β-blockers (β=0.001, P=1); 
and uric acid levels (β=–0.052, P=0.6). In addition, after 
adjustment for diastolic and systolic blood pressure, mean 
IMT was comparable in both groups with a mean difference 
of 0.026 mm (SE 0.017 mm, P=0.1). Moreover, a positive 
association was found between IMT and diastolic and systolic 
blood pressure (r=0.3, P<0.01 and r=0.3, P<0.01, respec-
tively). No correlations were observed between the decreased 
blood pressure and the use of β-blockers or diuretics.
Blood Analysis
To clarify the cause of the difference in IMT between 
cyanotic patients and controls, we analyzed risk factors for 
atherosclerosis through blood analysis (Table 2). Total cho-
lesterol levels were significantly lower in cyanotic patients 
compared to controls (Figure 2), and reduced total choles-
terol levels (<3.9 mmol/L) were more often seen in these 
patients (37% vs 17%, P=0.02). Total cholesterol was posi-
Figure 1.    Mean  carotid  intima – media 
thickness (IMT), adjusted for age. Carotid 
IMT  was  significantly  decreased  in  cya-
notic patients compared to controls with a 
mean difference of 0.04 mm (SE 0.015 mm, 
P=0.01).
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tively associated with mean IMT (r=0.4, P<0.01) and with 
oxygen saturation (r=0.2, P=0.04). On multivariate analysis 
the presence of Down syndrome, hypothyroidism, smoking 
or the use of thiazide diuretics or β-blockers had no con-
tributing effect on differences in total cholesterol between 
cyanotic patients and controls. Table 2 shows the equal dis-
tribution of LDL-cholesterol in both groups. Strikingly, 
HDL-cholesterol was significantly lower in cyanotic patients. 
Multivariate analysis indicated that 32% of the variation in 
HDL was due to the cyanotic state and the use of β-blockers 
(r=0.6, P<0.001). In addition, there were no gender differ-
ences in total, LDL- and HDL-cholesterol.
Additional blood analyses showed, as expected, significant-
ly increased hemoglobin, hematocrit and erythrocyte levels 
in cyanotic patients, as well as bilirubin and uric acid levels 
(Table 2). No correlation was found between either hemo-
globin, hematocrit or erythrocyte levels and total cholesterol. 
Total cholesterol was neither related with bilirubin nor with 
uric acid levels. Furthermore, 46% of the cyanotic patients 
(n=25) had thrombocytopenia, defined as platelet counts 
<150×109 /L. Thrombocyte levels were associated with the 
severity of cyanosis (r=0.5, P<0.01).
Discussion
This is the first study showing a reduced IMT in cyanotic 
CHD patients by means of non-invasive techniques. The 
reduction in IMT might be due to a combination of decreased 
atherosclerotic risk factors in cyanotic patients.
The present results are in accordance with the findings of 
Perloff, who found minimal or absent signs of atheroscle-
rosis on coronary angiography in 25 cyanotic women, mean 
age 43±4 years and 24 cyanotic men, mean age 41±6 years.1 
We confirmed these findings using non-invasive and quan-
titative carotid IMT measurements.
It is known that reduced atherosclerotic and thrombotic 
factors, for example hypocholesterolemia, hyperbilirubi-
nemia, elevated nitric oxide levels and thrombocytopenia 
are associated with cyanosis.1,2,15 To further elucidate the 
mechanism underlying the cause of the reduced mean IMT 
in cyanotic patients, we analyzed these risk factors. Elabo-
rating on the contribution of nitric oxide to IMT was beyond 
the scope of the present study.
Total cholesterol levels were significantly reduced in the 
present patients, and correlated positively with decreased 
oxygen saturation. Decreased total cholesterol is related to 
low IMT, as has been demonstrated in the general popula-
tion.16–18 Hyperbilirubinemia is frequently seen in cyanotic 
patients due to secondary erythrocytosis, as confirmed in the 
present study.19 Serum bilirubin is considered anti-athero-
sclerotic, because it is an endogenous antioxidant that inhibits 
LDL oxidation.20 We were unable, however, to demonstrate 
a reduction in serum LDL levels because the inhibitive prop-
erties of hyperbilirubinemia, which promotes LDL oxidation, 
were counteracted by elevated uric acid levels.21 Unexpect-
edly, we found low – normal HDL levels, cut-off 1.1 mmol/L, 
in the cyanotic population compared to the control group. The 
cyanotic state and the use of β-blockers were found to be 
independent predictors for reduced HDL. Beta-blocker usage 
Table 2. Blood Analysis
Cyanotic CHD patients 
(n=54)
Controls 
(n=54) P value
Serum lipids (mmol/L)
    Total cholesterol 4.4±1.2 4.9±1.0 0.02
    LDL-cholesterol 2.8±1　 2.9±0.9 0.5　
    HDL-cholesterol 1.2±0.3 1.6±0.4 <0.01　
    Triglycerides   1±0.5 0.9±0.4 0.1　
Serum tests
    Bilirubin total (μmol/L) 18.6±11　 12.7±6　 <0.01　
    Uric acid (mmol/L) 0.5±0.7   0.3±0.08 0.03
    Glucose (mmol/L) 4.6±0.9 4.8±0.5 0.2　
    Folate acid (nmol/L) 21.5±13　 24.8±6　 0.2　
Hematology
    Hemoglobin (mmol/L) 11.9±2　 8.9±0.8 <0.01　
    Hematocrit (L/L) 0.59±0.09 0.42±0.04 <0.01　
    Erythrocytes (10 12/L) 6.7±1.2 4.7±0.5 <0.01　
    Thrombocytes (10 9/L) 173±81　 255±54　 <0.01　
CHD, congenital heart disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Figure 2.    Total fasting cholesterol of cyanotic patients and 
controls. Total cholesterol was significantly reduced in cya-
notic patients compared to controls: 4.4±1 mmol/L vs 4.9± 
1 mmol/L, respectively (P=0.02).
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has previously been shown to negatively influence HDL-cho-
lesterol levels.22–24 Only 13% of the cyanotic CHD patients, 
however, used a β-blocker, which could not completely 
explain the decreased HDL levels. Fyfe et al also found 
unexplained reduced HDL levels in their cyanotic patient 
group, whereas HDL levels were increased in the hypoxemic 
erythrocytotic of high altitudes.2 A possible hypothesis is the 
existence of hypoalphalipoproteinemia, because apo A-I 
plays an important role in HDL function.25 Furthermore, a 
number of rare genetic disorders are associated with low 
HDL-cholesterol levels.26 The genes that account for the 
variation in serum HDL-cholesterol in the general population, 
however, have not been identified as yet. In addition, it was 
beyond the scope of the present study to clarify the unex-
pected reduction of HDL levels in cyanotic CHD patients.
Blood pressure was significantly reduced in the present 
patients and an association was found between diastolic and 
systolic blood pressure and IMT. On multivariate analysis 
the reduced blood pressure could not explain the difference 
in IMT between patients and healthy controls.
Although not a risk factor for atherosclerosis, thrombocyto-
penia is frequently seen in cyanotic patients.8,10,27,28 We found 
low thrombocyte levels, which were negatively associated 
with the severity of pulmonary-to-systemic shunting and 
therefore with the level of cyanosis. Moreover, Kajimoto et 
al recently found elevated platelet activation in cyanotic 
patients, especially in patients after the Fontan procedure.29 
These finding could well be applicable to the present patient 
population, and could partly explain the appearance of throm-
boembolic events in these patients.29–31 Contrary to the 
increased bleeding tendency caused by this thrombocyto-
penia, hyperviscosity, which is a frequent complication in 
cyanotic patients, increases thrombotic risk.9,32,33 We con-
firmed this increased hyperviscosity by demonstrating sig-
nificantly elevated hemoglobin, hematocrit and erythrocyte 
levels in cyanotic patients. The literature is ambiguous, how-
ever, on the thrombotic risk of hyperviscosity, indicating the 
necessity of further investigation.33–36
A limitation of the present study was the small difference 
in IMT between two small and relatively young groups. The 
IMT was within the normal range37 and both groups would be 
estimated to be at low risk for cardiovascular event. Addition-
ally, long-term outcome is unknown for the present patient 
group and regularly follow up is necessary to determine 
whether a reduced IMT in cyanotic patients is associated with 
a decreased risk for cardiovascular events. Moreover, a sep-
arate comparison of IMT and anti-atherosclerotic effects 
between patients with the Eisenmenger syndrome and cya-
notic CHD patients without PH seemed inappropriate, because 
subgroups were small and heterogeneous. Another limitation 
was the lack of angiographic information of the coronary 
tree at the time of carotid ultrasound.
Conclusion
The present study showed lower carotid IMT in cyanotic 
CHD patients compared to unaffected controls, as measured 
on non-invasive ultrasound. The reduction in IMT in cyanotic 
patients might be due to a combination of reduced athero-
sclerotic risk factors such as lower blood pressure, higher 
bilirubin levels and lower thrombocyte levels. Therefore, in 
contrast to acyanotic CHD patients, it might be unlikely that 
atherosclerosis will pose an additional health problem to 
cyanotic CHD patients when they grow older and reach the 
age at which atherosclerosis becomes clinically relevant.
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